| Name | Title | Contact Details |
|---|---|---|
Paul Shabram |
Senior Vice President of Technical Operations | Profile |
Launa Saunders |
Director of IT, Sales and Marketing Platforms | Profile |
Troy Seelye |
Senior Vice President and Chief Information Officer | Profile |
89 North is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Plexium is the premier, next-generation Targeted Protein Degradation (TPD) company seeking to discover a wide range of monovalent target protein degraders that address the limitations of heterobifunctional degraders and cereblon IMiDs. The company is powered by its proprietary drug discovery platform designed to identify novel small molecules that induce selective degradation of drug target proteins through E3 ligase mediated proteasomal degradation. From molecular glues to monovalent degraders, Plexium is advancing a pipeline of novel targeted protein degraders for the treatment of cancer, neurodegeneration, and other diseases. Due to its expertise in TPD, Plexium has entered into strategic collaborations with Amgen and AbbVie to discover and develop a wide range of new therapies from cancer to neurological diseases. Supported by high quality investors, Plexium is well positioned to transform medicine.
Interpace Biosciences is a company that provides molecular and related first line diagnostic tests for evaluating risk of cancer, as well as specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted...
GRACE NETWORK is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ohana is pioneering a new frontier in reproductive medicine. Built upon a world-leading understanding of sperm biology, Ohana has created a best-in-class proprietary platform with broad applications across reproductive medicine.